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This study assessed the feasibility of using diffusion kurtosis imaging (DKI) as a measure of tissue 
heterogeneity and proliferation to predict the response of high grade serous ovarian cancer (HGSOC) 
to neoadjuvant chemotherapy (NACT). Seventeen patients with HGSOC were imaged at 3 T and had 
biopsy samples taken prior to any treatment. The patients were divided into two groups: responders 
and non-responders based on Response Evaluation Criteria In Solid Tumours (RECIST) criteria. The 
following imaging metrics were calculated: apparent diffusion coefficient (ADC), apparent diffusion 
(Dapp) and apparent kurtosis (Kapp). Tumour cellularity and proliferation were quantified using histology 
and Ki-67 immunohistochemistry. Mean Kapp before therapy was higher in responders compared to 
non-responders: 0.69 ± 0.13 versus 0.51 ± 0.11 respectively, P = 0.02. Tumour cellularity correlated 
positively with Kapp (rho = 0.50, P = 0.04) and negatively with both ADC (rho = −0.72, P = 0.001) and 
Dapp (rho = −0.80, P < 0.001). Ki-67 expression correlated with Kapp (rho = 0.53, P = 0.03) but not with 
ADC or Dapp. In conclusion, Kapp was found to be a potential predictive biomarker of NACT response in 
HGSOC, which suggests that DKI is a promising clinical tool for use oncology and radiology that should 
be evaluated further in future larger studies.
Ovarian cancer has the highest mortality of any gynaecological malignancy in the developed world. Disease 
prognosis depends on tumour subtype and the stage at diagnosis with high grade serous ovarian cancer (HGSOC) 
accounting for the majority of deaths1. The best treatment for HGSOC is with a combination of chemotherapy 
and cytoreductive surgery2.
The first line chemotherapy choice for HGSOC is a platinum-based drug together with a taxane3, both of 
which inhibit cell division. This chemotherapy treatment combination is associated with significant morbidity 
due to medication side effects, and has a complete remission rate of only around 50%3,4. Newer targeted thera-
pies based around DNA damage repair inhibition5,6, vascular growth factor inhibition6 and immune checkpoint 
inhibition7 are now being developed that may provide alternative treatment options to HGSOC patients in the 
future. With the availability of new therapies, there is an increasing need for methods to both predict and detect 
the response to treatment in HGSOC at the earliest timepoints possible, so that the best personalized therapies 
can be selected for individual patients.
Diffusion weighted imaging (DWI) has previously been shown to identify early treatment response in HGSOC 
by reporting on the cytotoxic effect of platinum-based chemotherapy8. In this study an extended version of dif-
fusion MRI modelling, diffusion kurtosis imaging (DKI), is evaluated as a predictive biomarker of neoadjuvant 
chemotherapy (NACT) response before the initiation of treatment.
1Department of Radiology, Box 218, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom. 2Cambridge 
University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, United Kingdom. 
3Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, United Kingdom. 
Correspondence and requests for materials should be addressed to S.S.D. (email: ssd32@cam.ac.uk)
Received: 25 January 2019
Accepted: 11 July 2019
Published: xx xx xxxx
OPEN
2Scientific RepoRts |         (2019) 9:10742  | https://doi.org/10.1038/s41598-019-47195-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Conventional clinical DWI assumes that the diffusion of water follows a Gaussian distribution. This approach 
however over simplifies the movement of water in tissue, as the heterogenous spatial distribution of micro-
structures that obstruct diffusion (such as the membranes of cells and organelles) imparts a positive peak to the 
Gaussian model, termed kurtosis. Kurtosis is more apparent at higher diffusion weightings and DKI modelling is 
relatively easy to translate into clinical practice through the use of appropriate b-values9.
DKI has been shown to measure tissue heterogeneity and to correlate with expression of the proliferation 
marker Ki-67 in several malignancies, including ovarian cancer10–12. Given that Ki-67 is known to identify cancers 
that are sensitive to chemotherapeutic agents that target proliferating cells13,14, in this study we hypothesized that 
DKI may be able to predict the response of HGSOC to chemotherapy drugs that inhibit cell division like carbo-
platin and paclitaxel. There is already some evidence to support this property of DKI in nasopharyngeal cancer15 
and in this work we present the first exploratory study of the ability of DKI to predict the response of HGSOC in 
patients undergoing standard of care NACT before the start of treatment.
Materials and Methods
Study conduct. This was a single centre prospective, observational study on a consecutive sample of seven-
teen treatment-naïve patients with new diagnoses of HGSOC. Included participants had no previous cancer treat-
ment or surgery and no contraindications to MRI. The recruitment was part of the MISSION-ovary (Molecular 
Imaging and Spectroscopy with Stable Isotopes in Oncology and Neurology) research study for investigating the 
use of novel MRI methods in ovarian cancer: ClinicalTrials.gov Identifier, NCT03526809. Institutional review 
board approval was obtained for all study related procedures (South Cambridge Research Ethics Committee 
reference 15/EE/0378) and written informed consent was obtained from all participants. All study related proce-
dures were carried out in accordance with the research ethics guidelines outlined in the Declaration of Helsinki. 
The research MRI did not change clinical management, which was based on standard of care computed tomog-
raphy (CT).
MRI technique and image analysis. A 3 T MRI scanner (Discovery MR750, GE Healthcare, Waukesha 
WI) and a 32-channel cardiac array coil were used to perform DWI and T2-weighted imaging in participants 
between one and seven days before the start of chemotherapy treatment. 20 mg of intravenous hyoscine butylb-
romide was given 5 min prior to imaging to reduce artefacts from bowel motion. Full scan parameters are listed 
in Table 1.
Apparent diffusion (Dapp, in mm2/s) and apparent kurtosis (Kapp, unitless) were calculated with in-house soft-
ware written in MATLAB R2018a (The MathWorks Inc., Natick, MA), by performing a pixel-wise non-linear fit 
to the bi-exponential diffusion kurtosis model described in equation 116.
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where S(b) is signal intensity at each b-value, and S0 is signal intensity with no diffusion weighting. Apparent 
diffusion coefficient (ADC) values, in mm2/s were also calculated using conventional mono-exponential 
Gaussian diffusion modelling from the images with b-values of 100, 500 and 900 s/mm2. Regions of inter-
est (ROIs) were drawn on the Dapp maps to reduce errors due to image distortion known to occur between 
T2-weighted and diffusion images17. ROIs were drawn with OsiriX (version 3.8.1, Pixmeo, Geneva, Switzerland) 
by a radiologist, with 8 years of attending experience in oncological imaging and who was kept blind to treat-
ment response and tissue analysis results. The ROIs were placed around all solid cancerous lesions, with care 
taken to exclude cystic and necrotic regions and imported onto the ADC and Kapp maps, which were assumed 
to be co-registered as they were derived from the same set of DWI images. For each patient all tumour ROIs 
present in the abdomen and pelvis were combined into a volume of interest (VOI) to derive single ADC, Dapp 
and Kapp values from each patient for analysis. Intraobserver and interobserver variability were assessed by 
Imaging 
parameter T2-weighted
Diffusion weighted 
imaging
TR 4000 ms 6000 ms
TE 91.1 ms 94 ms
flip angle 90° 90°
slice thickness 6 mm 6 mm
FoV 34.0 cm × 29.9 cm 34.0 cm × 29.9 cm
matrix 256 × 256 128 × 112
signal averages 8 4
parallel imaging — ASSET, factor 2
bandwidth 99.8 kHz ±142 kHz
total scan time 1 min 54 sec 7 min 42 s
b-values — 100, 500, 900, 1300 and 1700 s/mm2
Table 1. Table of imaging parameters. T2-weighted and diffusion imaging parameters. TR = repetition time, 
TE = echo time, FoV = field of view.
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ROIs drawn by a second observer with four years of experience as a general medical doctor and three year of 
specialist experience as a radiology researcher in oncological imaging and diffusion MRI.
Response evaluation. Response to NACT was assessed according to Response Evaluation Criteria In Solid 
Tumours (RECIST) criteria version 1.118, using contrast enhanced CT scans performed as part of the patients’ 
regular clinical management. These were a baseline CT scan before the initiation of chemotherapy and a second 
CT scan up to one week after the third cycle of chemotherapy. Response was evaluated at the gynaecologic oncol-
ogy multi-disciplinary team (MDT) meeting by a consensus decision from gynaecologic radiologists, oncologists, 
surgeons and histopathologists after review of the CT scans. All MDT members were kept blind to the research 
MRI and tissue analysis results. Participants with 30% or greater reduction in disease, i.e. a RECIST Complete 
Response (CR) or Partial Response (PR) were classified as responders and those with Stable Disease (SD) or 
Progressive Disease (PD) were classified as non-responders.
Tissue processing and immunohistochemistry. Tumour samples were collected from either ovarian or 
peritoneal cancer deposits before treatment either by ultrasound-guided needle biopsy or a surgical procedure 
in the cases of lesions that were not accessible through the percutaneous route. Tissue was fixed in formalin and 
embedded into paraffin blocks. 3 µm sections were cut from the blocks and stained with H&E (haematoxylin and 
eosin) and Ki-67 (Dako Cat# M7240). Staining was carried out using Leica’s Polymer Refine Detection System 
(DS9800) automated Bond platform. This platform included a post primary of rabbit anti-mouse IgG (<10 µg/
mL) in 10% (v/v) animal serum plus tris-buffered saline/0.09% (ProClin™ 950) and a polymer of anti-rabbit 
poly-HRP-IgG (<25 µg/mL) in 10% (v/v) animal serum plus tris-buffered saline/0.09% (ProClin™ 950). 
Bright-field scanning was performed on an Aperio AT2 scanner (Leica) to digitize slides for automated analysis. 
Quantification of Ki-67 staining and of the number of cells per unit area, as an estimate of cellularity (cells/µm2), 
were performed using the multiplex IHC V1.2 module of Halo histology image analysis software (Indica labs 
v2.1.1637.11). Cells with Ki-67 staining greater than an optical density of 0.31 were considered positive. The 
operator of the analytic software was blinded to MRI and treatment response results.
Feature Value
Number of patients 17
Age at diagnosis, mean (range) (years) 66.6 (43 to 81)
ECOG performance status (number of patients)
  0–2 13
  3–4 4
FIGO stage (number of patients)
  I 0
  II 1*
  III 12
  IV 4
Serum CA 125 at diagnosis (IU/ml) (number of patients)
  0–100 4
  100–500 5
  >500 8
Volume of ROIs analysed (number of patients)
  0 to 25 ml 0
  >25 to 50 ml 3
  >50 to 100 ml 8
  >100 ml 6
Treatment pathway
  Neoadjuvant treatment 15
  Adjuvant treatment 2
RECIST response on CT
  Complete response (CR) 0
  Partial response (PR) 5
  Stable disease (SD) 8
  Progressive disease (PD) 2
Table 2. Characteristics of study population. Population demographics of patients recruited. ECOG = Eastern 
Cooperative Oncology Group, FIGO = Fédération Internationale de Gynécologie et d’Obstétrique, 
ROI = region of interest, RECIST = Response Evaluation Criteria In Solid Tumours, CA 125 = cancer antigen 
125, NACT = neoadjuvant chemotherapy, S.D. = standard deviation. *The one FIGO stage II patient in this 
cohort underwent treatment with primary surgery followed by adjuvant chemotherapy.
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Statistical methods. Statistical analysis was performed in R (version 2.15.3, R Foundation for Statistical 
Computing, Vienna, Austria) and a P value of 0.05 was used as the cut-off to indicate significance. Intraobserver and 
interobserver agreement were assessed using the intraclass correlation coefficient (ICC). When testing for differences 
Figure 1. Axial MRI images from a 63-year old high grade serous ovarian cancer patient who had a good response 
to neo-adjuvant chemotherapy. (a) DWI at b = 1300 s/mm2. Scale bar represents signal intensity; (b) ADC map 
with tumour ROI shown. Scale bar represents ADC in mm2/s × 1000; (c) Dapp map. Scale bar represents Dapp in 
mm2/s × 1000; (d) Kapp map. Scale bar represents Kapp × 1000; Axial CT scans following intravenous contrast 
medium: (e) before treatment; (f) after treatment, depicting a RECIST Partial Response (PR).
Diffusion 
metric Intraobserver ICC Interobserver ICC
ADC 0.971 (0.967 to 0.972) 0.977 (0.975 to 0.978)
Dapp 0.968 (0.965 to 0.971) 0.974 (0.971 to 0.976)
Kapp 0.989 (0.986 to 0.981) 0.989 (0.986 to 0.982)
Table 3. Intraobserver and interobserver variability for diffusion imaging metrics. ICC = intraclass coefficient 
correlation, ADC = apparent diffusion coefficient, Dapp = apparent diffusion, Kapp = apparent kurtosis. Values in 
brackets represent the 95% confidence interval.
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in means between groups, the Shapiro–Wilk test was used to assess for normality of data. Student’s t-test or the 
Mann-Whitney U test was then applied for evaluations on normally and non-normally distributed data respectively. 
Immunohistochemistry and histology results were compared to the diffusion imaging metrics using Spearman’s 
correlation.
Results
Study population. Seventeen patients were recruited to this study. Mean age was 66.6 ± 9.4 (mean ± S.D.) 
years and age range was 43 to 81 years old. Population demographics are summarized in Table 2. After MRI imag-
ing, 15 of the 17 participants went on to have NACT treatment with a combination of carboplatin and paclitaxel. 
The remaining 2 patients (one of whom had Stage 1 cancer) were treated by the decisions of their clinical teams 
with primary surgery and adjuvant chemotherapy and therefore could not be investigated for NACT treatment 
response as part of this study.
Imaging. There was a good fit of DWI images to the DKI model for the VOIs analysed. Figure 1 shows 
an example of a typical DWI image and the diffusion parameter maps for a 63-year old HGSOC patient who 
responded well to NACT. The CT scans for this patient before and after therapy are also shown.
Intraobserver and interobserver variability. There was good intraobserver and interobserver agreement 
for all diffusion metrics measured. Results are summarized in Table 3.
Predicting treatment response. Of the 15 patients to undergo NACT, there were five RECIST responders 
and ten non-responders. A significant difference was found in the pre-treatment mean Kapp between the respond-
ers and non-responders: 0.69 ± 0.13 versus 0.51 ± 0.11 (mean ± S.D.) respectively; Mann-Whitney U test, P = 0.02 
for a difference between these two groups. Dapp was not found to be significantly different between responders 
and non-responders: 1.44 ± 0.30 × 10−3 mm2/s versus 1.51 ± 0.32 × 10−3 mm2/s respectively, P = 0.68. The differ-
ence in ADC between responders and non-responders was similarly non-significant: 1.22 ± 0.24 × 10−3 mm2/s 
versus 1.30 ± 0.27 × 10−3 mm2/s respectively, P = 0.77. Boxplots of the median Kapp, Dapp and ADC values for the 
responder and non-responder groups are shown in Fig. 2.
Correlation with cellularity and Ki-67 expression. Localization of the Ki-67 stain was to the nucleus 
of cells in all cases as expected. Ki-67 staining was also subjectively observed to be greater in tissue that was con-
firmed as cancerous on H&E, which is consistent with the expression pattern of this protein that is known to be 
upregulated in ovarian cancer19.
Figure 3 shows the appearances of the H&E and Ki-67 staining for a responder (Fig. 3a,b) and a non-responder 
(Fig. 3c,d) to NACT. An example of the automated segmentation of Ki-67 positive cells in Halo is shown in 
Fig. 3e,f, which illustrates the accuracy of cell classification by the software.
Cellularity exhibited a positive correlation with Kapp (Spearman rho = 0.49, P = 0.04) and negative correla-
tions with both ADC (rho = −0.77, P = 0.02) and Dapp (rho = −0.73, P = 0.03). Kapp correlated positively with 
the percentage of cells expressing Ki-67 (rho = 0.53, P = 0.03), but ADC and Dapp did not correlate with Ki-67 
(P = 0.55 and P = 0.15 respectively). A scatterplot of mean tumour Kapp against Ki-67 quantification is shown 
in Fig. 3g, also identified on this plot are the responder and non-responder NACT cases and the two adjuvant 
treatment cases.
Figure 2. Box-and-whisker plots showing median and inter-quartile ranges of diffusion parameters for 
responders and non- responders to neoadjuvant chemotherapy. (a) Kapp; (b) Dapp; (c) ADC.
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Discussion
This study demonstrated that measurements of the non-Gaussian movement of water with DKI may predict the 
response to neoadjuvant chemotherapy in HGSOC patients. Tumours with a higher mean Kapp before the start of 
chemotherapy were found to respond better to treatment whereas neither conventional ADC, nor its equivalent 
calculated from the DKI acquisition (Dapp), could effectively differentiate responders from non-responders. All 
three diffusional metrics correlated with cellularity, which was expected as cells form the major barrier to the 
diffusion of water in tissue20–22. Histopathology results also confirmed that the previously reported relationships 
between diffusion and cellularity20,23 and between Kapp and Ki-6710,11 demonstrated in other cancers are also pres-
ent in this HGSOC patient cohort.
Conventional DWI assumes that the movement of water in tissue is Gaussian. This assumption is prob-
lematic in malignancy however, as the structural complexity and heterogeneity within tumours can produce 
non-Gaussian patterns of diffusion. DKI attempts to address this complication through the inclusion of an addi-
tional parameter in the diffusion model, Kapp, that quantifies the kurtosis aspect of the deviation of the imaging 
signal from a purely mono-exponential Gaussian distribution.
As the magnitude of the Kapp term in DKI relates to tissue heterogeneity16 and heterogeneity in turn is used to 
help determine tumour grade on histopathology, in some malignancies DKI has been studied for its diagnostic 
value in tumour grading. Previous research has already demonstrated that DKI can differentiate grade II and 
Figure 3. Examples of histology from a responder and a non-responder. (a) 1x magnification H&E slide of 
responder; (b) 1x magnification Ki-67 staining from responder (positive tissue shown in brown and negative 
tissue shown in blue); (c) 1x magnification H&E slide of non-responder; (d) 1x magnification Ki-67 staining 
from non-responder (positive tissue shown in brown and negative tissue shown in blue); (e) 20x magnification 
of Ki-67 staining in a HGSOC patient, with positive cells in dark brown and background counter staining in 
blue; (f) automated image segmentation in Halo for quantification of Ki-67 staining. Positive cells are shown 
in dark brown and negative cells are shown in blue. (g) Scatterplot of mean tissue Kapp against percentage of 
cells positive for Ki-67 staining (optical density > 31). White circles indicate responders, black circles indicate 
non-responders and crosses indicate the two patients treated with primary surgery before starting adjuvant 
chemotherapy.
7Scientific RepoRts |         (2019) 9:10742  | https://doi.org/10.1038/s41598-019-47195-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
III gliomas12,24, low grade and high grade prostate cancer25,26 and borderline from malignant epithelial ovarian 
tumours10. In the case of epithelial ovarian cancer however, for the one DKI study that was previously performed, 
Kapp was not shown to be superior to conventional ADC measurements at diagnosing grade10. Additionally, for 
HGSOC, which is the most clinically relevant subtype of epithelial ovarian cancer, due to its frequency and high 
mortality, there is no widely accepted subdivision of tumour grading, against which DKI could be easily assessed, 
as moderately differentiated serous ovarian cancer is no longer believed to be a valid subclassification of the 
disease27,28.
The treatment response findings presented here may be explained by the higher cellular density and micro-
structural heterogeneity that is present in rapidly proliferating tissue, which can be probed histologically with 
Ki-67 and non-invasively by Kapp. Rapidly dividing and heterogeneous tumours may be more sensitive to ther-
apies that target cellular replication, such as carboplatin which inhibits DNA synthesis required for new cell 
development29 and paclitaxel which disrupts the microtubule formation necessary for mitosis30. Further to this, 
more proliferative ovarian cancer subtypes like HGSOC are known to respond better to chemotherapy than low 
grade serous ovarian cancer31. The low proliferation rates in epithelial ovarian cancer have been shown previously 
to relate to chemoresistance32 and a number of other high Ki-67 expressing cancers are sensitive to chemother-
apy13,14. These previous studies all provide evidence to support a true relationship between cellular proliferation 
in HGSOC and a response to NACT treatment.
Besides the prediction of response to NACT, DKI in HGSOC could also find a clinical role in investigating 
tumour microstructure and growth in conjunction with other immunohistochemistry and histological markers. 
Unlike histopathological measurements that are taken from small biopsy samples of tumour tissue that have 
undergone changes during traumatic sampling and fixation, DKI can non-invasively probe cellularity and prolif-
eration in entire tumour volumes in vivo. HGSOC is known to be heterogeneous33,34 and a biopsy sample may not 
always be representative of the Ki-67 expression and cellularity across the complete tumour. DKI measurements 
which are performed by imaging the whole tumour volume may therefore provide more complete information on 
tumour biology that may be complementary to that gained from biopsy specimens alone. DKI metrics assess the 
heterogeneity of water movement and how this differs from a normal Gaussian distribution within an individual 
voxel. In this study the patient number was too small to permit reliable hypothesis testing of the multiple parame-
ters that would be produced by histogram or textural analysis. Future work with a larger number of patients could 
however extend this study to assess intervoxel heterogeneity of water movement by using histogram analysis35,36 
or Haralick textural features37.
The conclusions that can be drawn from this study are limited by the small sample size, which restricts the 
scope for wider interpretation of the results; however, given that imaging findings correlated with the histological 
analysis and provided a mechanistic explanation for the results observed, there is strong support that the findings 
here are based on a real biological difference between groups which can be detected on imaging, rather than a 
statistical aberration. The tissue used to quantify Ki-67 expression and cellularity was also subject to sampling 
error as histological specimens from a small tissue sample were compared to the imaging results derived from 
the whole tumour burden of patients. This type of sampling error is unfortunately unavoidable when biopsies 
from large, heterogenous tumours must be compared to imaging findings; despite this limitation, the correlation 
between imaging and histology is once again grounded in a biological rationale for the imaging results and reem-
phasizes the potential clinical utility of combining the detailed histological data acquired from a small biopsy 
sample with the multiparametric imaging data acquired at lower resolution but from a larger volume of tumour. 
Other factors that may have influenced treatment response but were not considered here include: the initial 
tumour burden of patients, the stage of the disease at recruitment, patient co-morbidities and genetic factors such 
as the presence of BRCA and TP53 mutations that can impact on the effectiveness of chemotherapy38–40.
In summary, the results of this study suggest that in HGSOC there may be a clinically relevant relationship 
between DKI-derived diffusion metrics and the response of the cancer to neo-adjuvant chemotherapy, par-
ticularly involving drugs that target cell proliferation. These findings have the potential to be applied to stratify 
treatment options in ovarian cancer and to rapidly escalate patients to alternative targeted or combinational ther-
apeutic approaches, while reducing morbidity from the side effects of less efficacious drugs. It is also possible that 
DKI may offer clinical value as an adjunct to histopathology for the measurement of ovarian cancer proliferation 
and cellularity as it derives from a larger tissue volume. This study therefore provides preliminary data for larger 
trials to confirm these results and to further explore the applications of DKI in HGSOC patients.
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